Hugh Rosen joins Regulus board of directors
Dr. Rosen is a Professor in the Departments of Chemical Physiology & Immunology at The Scripps Research Institute in La Jolla, California where he focuses on the study of lymphocyte trafficking and barrier regulation by signaling lipids, and contributing towards the development of translational infrastructure at TSRI.
He also serves as Chairman of the Committee for Advance Human Therapeutics of TSRI.
Prior to joining The Scripps Research Institute, Dr. Rosen served in various capacities at Merck Research Laboratories, including Executive Director and Therapeutic Area head, and chair of Merck's Anti-bacterial and Anti-fungal Worldwide Business Strategy Team.
Dr. Rosen was the Scientific Founder of Receptos, Inc., now a wholly owned subsidiary of Celgene Corporation, and currently serves on its Scientific Advisory Board. He also serves on the Scientific Advisory Board of ActivX Biosciences Inc.
Dr. Rosen received his M.D. from University of Cape Town and his Ph.D. from University of Oxford. ■
What to read next
LATEST MOVES FROM California
- Wells Fargo names Michael Roemer as chief compliance officer
- ARMO BioSciences appoints Joseph Leveque as CMO
- Amyris appoints Eduardo Alvarez as COO
- ChromaDex appoints Kevin Farr as CFO
- Apple appoints Katherine Adams as general counsel, SVP
More inside POST
BlackBerry plans to move to NYSE Companies